-
Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells Pérez-Persona E, Mateo G, García-Sanz R, Mateos MV, de las Heras N, de Coca AG, Hernández JM, Galende J, Martín Nuñez G, Bárez A, Alonso JM, Martín A, López-Berges C, Orfao A, San-Miguel JF, Vidriales MB. British Journal of Haematology 148(1):110-4. FI: 4.597 (Q1) Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with non-intensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan. Prednisone versus melphalan-prednisone Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O, Kropff M, Kentos A, Cavo M, Golenkov A, Komarnicki M, Mateos MV, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF. Blood 116(19):3743-50. FI: 10.555 (Q1) Survival and years of life lost in different age cohorts of patients with multiple myeloma Ludwig H, Bolejack V, Crowley J, Bladé J, Miguel JS, Kyle RA, Rajkumar SV, Shimizu K, Turesson I, Westin J, Sonneveld P, Cavo M, Boccadoro M, Palumbo A, Tosi P, Harousseau JL, Attal M, Barlogie B, Stewart AK, Durie B. Journal of Clinical Oncology 28(9):1599-605. FI: 17.793 (Q1) The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin¿s lymphoma García-Sanz R, González ¿López TJ, Vázquez L, Hermida G, Graciani IF, San Miguel JF. European Journal of Haematology 84(3):266-70. FI: 2.345 (Q3) The DAC system and associations with multiple myeloma Ocio EM, San Miguel JF. Investigational New Drugs 28 Suppl 1:S28-35. FI: 3.072 (Q2) The role of immature platelet fraction in acute coronary syndrome González-Porras JR, Martín-Herrero F, González-López TJ, Olazábal J, Diez-Campelo M, Pabón P, Alberca I, San Miguel JF. Thrombosis and Haemostasis 103(1):247-9. FI: 4.451 (Q1) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, Palumbo A, Van Damme P, San Miguel JF, Sonneveld P. Lancet Oncology 11(11):1086-95. FI: 14.470 (Q1) Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders Paíva B, Almeida J, Pérez-Andrés M, Mateo G, López A, Rasillo A, Vidriales MB, López-Berges MC, San Miguel JF, Orfao A. Cytometry Part B Clinical Cytometry 78(4):239-52. FI: 1.727 (Q2) Value of serum free light chains assay in plasma cell disorders López-Corral L, García-Sanz R, San Miguel JF. Medicina Clínica 135(8):368-74. FI: 1.231 (Q3)
-
Frontline treatment in elderly patients with multiple myeloma Facon T, San Miguel JF, Mateos MV, Hulin C. Seminars in Hematology 46(2):133-42. FI: 2.703 (Q2)
|
